SS Innovations International (NASDAQ: SSII) announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year. The growth was driven by a 30.4% rise in installations of its SSi Mantra surgical robotic system, reaching 30 units during the quarter. Gross profit climbed 20% to $7.1 million, with a gross margin of 50.9%. The company reported a net loss of $2.7 million, or $0.01 per diluted share, compared to a net loss of $0.3 million in the prior-year quarter.
The strong performance extended to the first half of 2026, with revenue surging 65.6% to $25 million and SSi Mantra installations up 47.4% to 56 systems. As of June 30, the company held $13.6 million in cash and cash equivalents, had no long-term debt, and had a cumulative installed base of 224 SSi Mantra systems across 12 countries. This expansion underscores the company's commitment to making robotic surgery accessible globally.
A notable milestone was the cumulative performance of 12,272 procedures using the SSi Mantra, including 175 telesurgeries. The company also successfully completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's potential for remote surgical applications. This achievement highlights the scalability and reliability of the technology, which could transform surgical care in underserved regions.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration (FDA) to complete its review of the company's 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027. Additionally, the company believes it can obtain European Union CE marking certification by the end of 2026. Regulatory approvals would open significant market opportunities, allowing SS Innovations to compete in major healthcare markets.
The company's financial results and operational progress reflect growing demand for cost-effective surgical robotic solutions. With a focus on affordability and advanced technology, SS Innovations is positioning itself as a key player in the global medical device industry. The successful telesurgery and increasing procedure volumes indicate strong clinical acceptance and potential for widespread adoption.
Investors and industry observers will be watching for further updates on regulatory milestones and international expansion. As the company continues to scale its operations, the implications for global healthcare delivery are substantial, particularly in emerging markets where access to advanced surgical technology is limited.
